Effect of First-Line Ziconotide Intrathecal Drug Therapy for Neuropathic Pain on Disability, Emotional Well-Being, and Pain Catastrophizing

Shao, Miriam M; Khazen, Olga; Hellman, Abigail; Czerwinski, Margaret; Dentinger, Rachel Mason; DiMarzio, Marisa; Gillogly, Michael; Hadanny, Amir; Argoff, Charles E.; Pilitsis, Julie G.

doi:10.1016/j.wneu.2020.10.079

Cited by 5 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional evidence on the beneficial role of Ziconotide in the treatment of neuropathic pain comes from the clinical trial by Shao and colleagues, who showed that IT Ziconotide is able to improve pain and also emotional well-being [ 29 ]. The authors included 14 patients, who were followed for a mean period of time of 10.91 +/− 0.7 months, in which an improvement not only in the nociceptive symptomatology but also in pain catastrophizing, disability, and emotional well-being [ 29 ]. Despite its importance, this study and all literature is still lacking long-term efficacy and safety assessments for Ziconotide [ 30 ].…”

Section: Resultsmentioning

confidence: 99%

A Benefit/Risk Assessment of Intrathecal Ziconotide in Chronic Pain: A Narrative Review

Rubiu,

Restelli,

Nazzi

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Ziconotide is an intrathecal drug administered for the treatment of chronic pain. The current literature lacks an exhaustive benefit/risk assessment on this drug. We herein focus on Ziconotide’s pharmacology and clinical applications. Methods: Literature research was conducted to identify studies on Ziconotide administration for the treatment of chronic pain, published between January 1990 and March 2023 and located via PubMed, Embase, Medline, Cinahl, and Web of Science, using the following keywords: Ziconotide, Omega conotoxin, Prialt, SNX-111, intrathecal therapy, and neuropathic pain. Only publications written in English were selected. Results: Among the 86 selected studies, we found 4 Randomized Controlled Trials (RCTs) and 3 prospective long-term studies concerning the intrathecal use of Ziconotide as a monotherapy in chronic pain. Other studies described the intrathecal infusion of Ziconotide combined with other drugs. Overall, Ziconotide has been proved to have strong efficacy for relieving chronic pain, although patients with co-morbid psychiatric disorders require a careful monitoring when treated with Ziconotide. Conclusions: Overall, the use of Ziconotide, as a monotherapy or in conjunction with other therapies for the treatment of chronic pain, was reported to be efficacious. Overall, its use in patients with chronic pain refractory to other pharmacologic agents outweighs the possible adverse consequences, thus resulting in a favorable benefit/risk assessment.

show abstract

Section: Resultsmentioning

confidence: 99%

A Benefit/Risk Assessment of Intrathecal Ziconotide in Chronic Pain: A Narrative Review

Rubiu,

Restelli,

Nazzi

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…Intrathecal ziconotide therapy was also reported to effectively treat chronic refractory migraines [ 70 ]. Another finding suggests that intrathecal ziconotide can improve emotional components and function while relieving pain [ 95 ]. This finding appears to be in contrast to the opinion that ziconotide has the potential to induce or exacerbate depression.…”

Section: Clinical Application and Efficacymentioning

confidence: 99%

A comprehensive review on ziconotide

Lin,

Chen,

Butt

et al. 2024

Heliyon

View full text Add to dashboard Cite

“… The mean percent reduction in VASPI score from baseline was 31.2% and 6.0% for ziconotide- and placebo-treated patients, respectively (p ≤ 0.001). Shao et al, 2021 98 Prospective 14 I-B Examined the role of first-line ziconotide IDT on the tridimensional pain experience in ziconotide IDT-naive patients with neuropathic pain. 11 of 14 patients completed long-term follow-up.…”

Section: Section 3 Neuromodulationmentioning

confidence: 99%

A Systematic Guideline by the ASPN Workgroup on the Evidence, Education, and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET

Sayed,

Deer,

Hagedorn

et al. 2024

JPR

View full text Add to dashboard Cite

Introduction Painful diabetic neuropathy (PDN) is a leading cause of pain and disability globally with a lack of consensus on the appropriate treatment of those suffering from this condition. Recent advancements in both pharmacotherapy and interventional approaches have broadened the treatment options for PDN. There exists a need for a comprehensive guideline for the safe and effective treatment of patients suffering from PDN. Objective The SWEET Guideline was developed to provide clinicians with the most comprehensive guideline for the safe and appropriate treatment of patients suffering from PDN. Methods The American Society of Pain and Neuroscience (ASPN) identified an educational need for a comprehensive clinical guideline to provide evidence-based recommendations for PDN. A multidisciplinary group of international experts developed the SWEET guideline. The world literature in English was searched using Medline, EMBASE, Cochrane CENTRAL, BioMed Central, Web of Science, Google Scholar, PubMed, Current Contents Connect, Meeting Abstracts, and Scopus to identify and compile the evidence for diabetic neuropathy pain treatments (per section as listed in the manuscript) for the treatment of pain. Manuscripts from 2000-present were included in the search process. Results After a comprehensive review and analysis of the available evidence, the ASPN SWEET guideline was able to rate the literature and provide therapy grades for most available treatments for PDN utilizing the United States Preventive Services Task Force criteria. Conclusion The ASPN SWEET Guideline represents the most comprehensive review of the available treatments for PDN and their appropriate and safe utilization.

show abstract

Effect of First-Line Ziconotide Intrathecal Drug Therapy for Neuropathic Pain on Disability, Emotional Well-Being, and Pain Catastrophizing

Cited by 5 publications

References 34 publications

A Benefit/Risk Assessment of Intrathecal Ziconotide in Chronic Pain: A Narrative Review

A Benefit/Risk Assessment of Intrathecal Ziconotide in Chronic Pain: A Narrative Review

A comprehensive review on ziconotide

A Systematic Guideline by the ASPN Workgroup on the Evidence, Education, and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET

Contact Info

Product

Resources

About